As of November 4, 2026, Lycia Therapeutics, Inc. is a publicly traded company (Nasdaq: LYCA); its largest reported holder is Venrock Healthcare Capital Partners III, L.P., with 11.9% on Schedule 13G of October 30, 2026. The largest insider holding is VHCP Co-Investment Holdings III, LLC, a 10% owner, with 6,850,237 shares held indirectly through a funds, per Form 4 of October 30, 2026 (Schedule 13G, October 30, 2026).
Is this your company?
About to sign with, pay or invest in Lycia Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lycia Therapeutics, Inc. a real, registered company?
- Lycia Therapeutics, Inc. files with the SEC under CIK 1806540 (its SEC filings).
- Its shares are listed under the ticker LYCA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lycia Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-04).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Venrock Healthcare Capital Partners III, L.P. (filed 2026-10-30).
Who are Lycia Therapeutics, Inc.'s owners and officers?
Lycia Therapeutics, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-30).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Executive Officer, Director (Form D, 2026-06-25)
- : Executive Officer (Form D, 2026-06-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-30 | Venrock Healthcare Capital Partners Iii, L.P. | 11.9% |
Want the whole picture on Lycia Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lycia Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lycia Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lycia Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- VHCP Co-Investment Holdings III, LLC, a 10% owner: 6,850,237 shares, held indirectly through a funds, on a joint filing (Form 4, 2026-10-30).
- VHCP Management III, LLC, a 10% owner: 6,850,237 shares, held indirectly through a funds, on a joint filing (Form 4, 2026-10-30).
- Venrock Healthcare Capital Partners EG, L.P., a 10% owner: 6,850,237 shares, held indirectly through a funds, on a joint filing (Form 4, 2026-10-30).
- VHCP Management EG, LLC, a 10% owner: 6,850,237 shares, held indirectly through a funds, on a joint filing (Form 4, 2026-10-30).
- Venrock Healthcare Capital Partners III, L.P., a 10% owner: 6,850,237 shares, held indirectly through a funds, on a joint filing (Form 4, 2026-10-30).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has Lycia Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-06-25 | $75M | $75M |
| Form D, 2024-05-23 | $106.60M | $106.60M |
Latest IPO step: Lycia Therapeutics, Inc. filed its final IPO prospectus, ticker LYCA (424B4, 2026-10-23).
IPO filings: 424B4, 2026-10-23, S-1/A, 2026-10-20, S-1, 2026-10-05; ticker LYCA on Nasdaq Global Select Market.
Keep reading
More on Lycia Therapeutics, Inc. and the records around it.
Lycia Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026), X4 Pharmaceuticals, Inc. (Sep 2026)
Related pages
Funding and filing history5%+ holdersIPO filings
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lycia-therapeutics-inc